



MASH fibrosis progression: an indicator of adverse outcomes

Patients with MASLD/MASH face an increased risk of health-related complications⁴ and mortality⁵⁻⁷, including **risk of cardiovascular events**⁵, a significant risk of **developing cirrhosis**⁸ and **HCC**⁹, which may require **liver transplantation**¹⁰ or lead to **earlier death**.




Up to 38% of patients with MASH and fibrosis develop cirrhosis⁸




MASH is the **fastest growing cause of liver transplantation** in the US¹⁰


Much of this disease burden increases with **progression to MASH with advanced fibrosis or cirrhosis**.¹¹ Without prompt detection and management, patients who progress to advanced fibrosis are:




11.1x more likely to experience death from **liver-related causes**^{7*}



3.4x more likely to experience death from **any cause**^{7*}



4.3x more likely to experience death from **cardiovascular disease**^{6†}





Identifying patients with MASH early in the course of disease is essential to minimize the risk of poor health outcomes associated with MASH

* Relative risk in patients with MASH F4 compared to patients with MASH without fibrosis (F0).
† Compared to sex- and age-matched control population.
F, fibrosis stage; HCC, hepatocellular carcinoma; MASH, metabolic dysfunction-associated steatohepatitis; MASL, metabolic dysfunction-associated liver; MASLD, metabolic dysfunction-associated liver disease; NASH, nonalcoholic steatohepatitis.
1. Younossi ZM et al. Hepatology. 2023;77:1335-1347; 2. Loomba R and Adams LA. Hepatology. 2019;70:1885-1888; 3. Marengo A et al. Clin Liver Dis. 2016;20:313-324; 4. Younossi ZM et al. Hepatology. 2016;64:73-84; 5. Mantovani A et al. Lancet Gastroenterol Hepatol. 2021;6:903-913; 6. Ekstedt et al. Hepatology. 2015;61:1547-1554; 7. Taylor RS et al. Gastroenterology. 2020;158:1611-1625; 8. Bertot LC and Adams LA. Int J Mol Sci. 2016;17:774; 9. Younossi ZM et al. Clin Gastroenterol Hepatol. 2021;19:580-589; 10. Lonardo A et al. Nat Rev Endocrinol. 2022;18:638-650; 11. Tapper EB et al. J Med Econ. 2023;26:348-356.

©2025 Novo Nordisk. For Field Medical Affairs in Scientific Exchange.